FDA gives full approval for Alzheimer’s drug Leqembi, and Medicare will pay for it

Vials and packaging for the Alzheimer’s drug Leqembi Eisai via AP WASHINGTON — U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease. The Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer’s... + full article